Streetbeat News

TLSI

TriSalus Life Sciences, Inc.

https://trisaluslifesci.com

Industry

Medical - Devices

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

Open

4.00

Mkt cap

126M

Volume

78K

High

4.16

P/E Ratio

-2.15

52-wk high

10.42

Low

3.65

Div yield

N/A

52-wk low

3.32

TriSalus Life Sciences, Inc. (TLSI) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included executives and analysts from various financial institutions.

Portfolio Pulse from

November 14, 2024 | 3:45 pm

Northland Capital Markets has initiated coverage on TriSalus Life Sciences with an Outperform rating and set a price target of $12.5.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 4:48 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. Scholar Rock Holding (SRRK) saw a massive increase of 198.1%, while Trevena (TRVN) experienced a sharp decline of 45.5%. Other notable gainers include LogicMark (LGMK) and Biohaven (BHVN), while Entero Therapeutics (ENTO) and Onconetix (ONCO) were among the losers.

Portfolio Pulse from Benzinga Insights

October 07, 2024 | 12:08 pm

TriSalus Life Sciences (NASDAQ:TLSI) has published research demonstrating that its Pressure-Enabled Drug Delivery (PEDD) method significantly improves the delivery of glass microspheres into liver tumors compared to conventional methods. The study, conducted on a porcine liver tumor model, shows enhanced penetration and potential for more effective cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:14 am

Oppenheimer has initiated coverage on TriSalus Life Sciences (NASDAQ:TLSI) with an Outperform rating and set a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:49 am

TriSalus Life Sciences (NASDAQ:TLSI) reported Q2 2024 GAAP EPS of $(0.21), beating the analyst estimate of $(0.41) by 48.78%. The company also reported quarterly sales of $7.36 million, meeting the analyst consensus estimate and marking a 59.67% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:02 pm

Canaccord Genuity analyst William Plovanic maintains a Buy rating on TriSalus Life Sciences (NASDAQ:TLSI) with a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 1:44 pm

TriSalus Life Sciences (NASDAQ:TLSI) presented data from its Phase 1b PERIO-02 clinical trial at the ASCO 2024 Annual Meeting. The trial focuses on using the company's Pressure Enabled Drug Delivery™ (PEDD™) technology to enhance drug delivery in liver and pancreatic cancer treatments.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 11:08 am

Canaccord Genuity has initiated coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and set a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 1:01 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 1%. Notable stock movements included Akanda Corp. (AKAN) rising 34% after a reverse stock split, Merus N.V. (MRUS) surging 34% following an abstract publication, and Deckers Outdoor Corporation (DECK) increasing 13% due to strong quarterly results. Conversely, Verastem, Inc. (VSTM) shares plummeted 65% after initiating a rolling NDA submission, TriSalus Life Sciences, Inc. (TLSI) fell 21% amid an exchange offer, and Genelux Corporation (GNLX) dropped 41% following a stock offering announcement.

Portfolio Pulse from Avi Kapoor

May 24, 2024 | 6:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.